IP Library Granted Patent US 9,114,170
Granted Patent B2
US 9,114,170 · App. 13/843,224 · Granted Aug 25, 2015

Highly loaded amorphous efavirenz composition and process for preparing the same

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,114,170
App. No.
13/843,224
Granted
Aug 25, 2015
Kind
B2
Abstract

A stable and high loading ternary solid dispersion composition comprising (a) about 50% wt. to about 90% wt. of amorphous Efavirenz; (b) about 10% wt. to about 50% wt. of polyvinyl pyrrolidone (PVP), a first polymer; (c) about 1% wt. to about 30% wt. of a water-soluble second polymer; and (d) optionally about 0.1% wt. to about 50% wt. of at least one pharmaceutically acceptable excipient. Also discloses a high loading ternary composition comprising (a) a solid dispersion composition comprising (i) about 50% wt. to about 90% wt. of amorphous Efavirenz; (ii) about 10% wt. to about 50% wt. of polyvinyl pyrrolidone, a first polymer; (b) about 1% wt. to about 30% wt. of a water-soluble second polymer blended with solid dispersion of composition of (a); and (c) optionally about 0.1% wt. to about 50% wt. of at least one pharmaceutically acceptable excipient. Additionally discloses a method for preparing solid dosage forms comprising (i) amorphous Efavirenz and (ii) polyvinyl pyrrolidone (PVP), a first polymer; (iii) a water-soluble second polymer; and (iv) optionally, at least one pharmaceutical excipients.

Claims (16)

1. A stable and high loading ternary solid dispersion composition comprising:

a. about 50% wt. to about 90% wt. of amorphous Efavirenz;

b. about 10% wt. to about 50% wt. of polyvinyl pyrrolidone, a first polymer;

c. about 1% wt. to about 30% wt. of a water-soluble second polymer; and

d. optionally about 0.1% wt. to about 50% wt. of at least one pharmaceutically acceptable excipient.

2. The ternary solid dispersion composition according to claim 1 , wherein the ratio of Efavirenz (a) to first polymer (b) to water-soluble second polymer (c) is about 1.0:0.5-1.0:0.05-0.5.

3. The ternary solid dispersion composition according to claim 1 , wherein the average molecular weight of polyvinyl pyrrolidone is in the range of from about 4,000 to about 130,000,00.

4. The ternary solid dispersion composition according to claim 1 , wherein the molecular weight of polyvinyl pyrrolidone is in the range of from about 25,000 to about 35,000.

5. The ternary solid dispersion composition according to claim 1 , wherein said water-soluble second polymer is selected from the group consisting of cellulose esters, cellulose ethers, polyacrylates, polymethacrylates, acrylates copolymers, homo and co polymers of acrylic acids, homo and co polymers of methacrylic acids, copolyacrylamides, polyvinyl alcohols, polyvinylpyrrolidone, polyvinylpyrrolidone/vinyl acetate copolymer, carboxyvinyl polymers, oligosaccharides, and/or polysaccharides.

6. The ternary solid dispersion composition according to claim 1 , wherein said water-soluble second polymer is selected from the group consisting of hydroxypropyl methyl cellulose succinate, cellulose acetate succinate, methyl cellulose acetate succinate, ethyl cellulose acetate succinate, hydroxypropyl cellulose acetate succinate, hydroxypropyl methyl cellulose acetate succinate (HPMCAS), hydroxypropyl cellulose acetate phthalate succinate, cellulose propionate succinate, hydroxypropyl cellulose butyrate succinate, hydroxypropyl methyl cellulose phthalate (HPMCP), cellulose acetate phthalate, methyl cellulose acetate phthalate, ethyl cellulose acetate phthalate, hydroxypropyl cellulose acetate phthalate, hydroxypropyl methyl cellulose acetate phthalate, cellulose propionate phthalate, hydroxypropyl cellulose butyrate phthalate, cellulose acetate trimellitate, methyl cellulose acetate trimellitate, ethyl cellulose acetate trimellitate, hydroxypropyl cellulose acetate trimellitate, hydroxypropyl methyl cellulose acetate trimellitate, hydroxypropyl cellulose acetate trimellitate succinate, cellulose propionate trimellitate, cellulose butyrate trimellitate, cellulose acetate terephthalate, cellulose acetate isophthalate, cellulose acetate pyridinedicarboxylate, salicylic acid cellulose acetate, hydroxypropyl salicylic acid cellulose acetate, ethylbenzoic acid cellulose acetate, hydroxypropyl ethylbenzoic acid cellulose acetate, ethyl phthalic acid cellulose acetate, ethyl nicotinic acid cellulose acetate, ethyl picolinic acid cellulose acetate, carboxy methyl cellulose, carboxy ethyl cellulose, ethyl carboxy methyl cellulose, hydroxypropyl methyl cellulose acetate, hydroxypropyl methyl cellulose (HPMC), hydroxypropyl cellulose, methyl cellulose, hydroxyethyl methyl cellulose, hydroxyethyl cellulose acetate, and hydroxyethyl ethyl cellulose, copolymers of methacrylates, copolymers of acrylates, poly(methacylic acid-co-methyl methacrylate), alone or in combination.

7. The ternary solid dispersion composition according to claim 1 , wherein the composition is storage-stable, transit-stable and/or able to increase dissolution rate and/or maintain supersaturation of Efavirenz (a) during dissolution.

8. The ternary solid dispersion composition according to claim 1 , wherein said pharmaceutically acceptable excipients is selected from the group consisting of plasticizers, disintegrants, surfactants, lubricants, glidants, carriers, anti-adherents, fillers, wetting agents, pH modifiers, binders, solubility modifiers, recrystallization inhibitors, coating agent and/or diluents.

9. The ternary solid dispersion composition according to claim 8 , wherein said plasticizer is selected from the group consisting of Triethyl Citrate, Glycerol Monostearate, Dibutyl Sebacate, Diethyl Phthalate, Polyethylene Glycol, Triacetin, Vitamin E-TPGS, Tween 80, Sodium Lauryl Sulfate, Sodium Docusate, Poloxamer F-68, Poloxamer F-127, Hydroxypropyl cellulose, polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer, alone or in combination.

10. The ternary solid dispersion composition according to claim 1 , wherein the pharmaceutical excipient is plasticizer present in an amount of from about 0.1% wt. to about 10.0% wt. of the total composition.

11. The ternary solid dispersion composition according to claim 1 , wherein said solid dispersion is formulated into tablets, films, capsules, pellets, granules, fine granules or a powder.

12. The ternary solid dispersion composition according to claim 1 , wherein the composition is prepared by spray-drying, hot-melt extrusion, solvent-evaporation, melt-granulation, melt-congealing, spray-congealing, blending, co-milling, spray coating, fluid bed granulation, layering or coating.

Assignments (4)
RELEASE OF SECURITY INTEREST Recorded Jan 10, 2020
From: THE BANK OF NOVA SCOTIA
To: AVOCA LLC; HERCULES LLC; ISP INVESTMENTS LLC; PHARMACHEM LABORATORIES LLC
Reel/Frame 051557/0504 →
SECURITY AGREEMENT Recorded Jul 3, 2017
From: AVOCA, INC.; HERCULES LLC; ISP INVESTMENTS LLC; PHARMACHEM LABORATORIES, INC.
To: THE BANK OF NOVA SCOTIA, AS ADMINISTRATIVE AGENT
Reel/Frame 043084/0753 →
CONVERSION Recorded Jan 30, 2017
From: ISP INVESTMENTS INC.
To: ISP INVESTMENTS LLC
Reel/Frame 041556/0499 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 5, 2013
From: BI, YUNXIA; RAHMAN, MOHAMMED ABDUL; LESTER, JAMES DAVID; DURIG, THOMAS; BULL, RANDY
To: ISP INVESTMENTS INC.
Reel/Frame 030548/0356 →